Rohini Sachdeva, MD
Internal Medicine · Hamilton, OHNPI 1164520516
Payments from drug & device makers
Across 380 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$749
- Bayer$394
- Abbott$323
- Merck$305
- Pfizer$298
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,142100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $1,664 |
| Novo Nordisk | 51 | $749 |
| Bayer | 16 | $394 |
| Abbott | 19 | $323 |
| Merck | 12 | $305 |
| Pfizer | 17 | $298 |
| Exact Sciences | 14 | $294 |
| GSK | 15 | $288 |
| Sanofi-aventis U.S. LLC | 19 | $286 |
| AbbVie(2 entities) | 16 | $262 |
| Boehringer Ingelheim | 15 | $255 |
| Lilly USA, LLC | 15 | $254 |
| Dexcom, Inc. | 8 | $205 |
| Novartis | 10 | $193 |
| Amarin Pharma, Inc. | 11 | $170 |
| Johnson & Johnson | 12 | $170 |
| Idorsia Pharmaceuticals US Inc | 5 | $158 |
| Amgen | 8 | $147 |
| Astellas Pharma US Inc | 7 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Phathom Pharmaceuticals, Inc. | 3 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $37 |
| Biogen | 2 | $36 |
| Amphastar Pharmaceuticals, Inc. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Radius Health, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,154 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $99,549 |
| FarxigaDapagliflozin Propanediol | 116 | $99,141 |
| JanuviaSitagliptin Phosphate | 202 | $75,163 |
| MounjaroTirzepatide | 53 | $57,476 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $38,504 |
| EliquisApixaban | 41 | $36,474 |
| TradjentaLinagliptin | 42 | $35,540 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $28,470 |
| XareltoRivaroxaban | 31 | $28,044 |
| JardianceEmpagliflozin | 22 | $26,592 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $23,534 |
| LinzessLinaclotide | 24 | $18,494 |
| TrulicityDulaglutide | 15 | $18,173 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $17,026 |
| MyrbetriqMirabegron | 13 | $14,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $1,664 | $112,968157 claims |
| Novo NordiskOzempic | $749 | $99,54991 claims |
| MerckJanuvia, Janumet | $305 | $81,923214 claims |
| Lilly USA, LLCMounjaro, Trulicity | $254 | $75,65068 claims |
| Boehringer IngelheimTradjenta, Jardiance | $255 | $62,13164 claims |
| GSKBreo Ellipta | $288 | $38,50475 claims |
| PfizerEliquis | $298 | $36,47441 claims |
| Johnson & JohnsonXarelto | $170 | $28,04431 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $286 | $23,53427 claims |
| AbbVieLinzess, Synthroid | $262 | $19,69949 claims |
| Astellas Pharma US IncMyrbetriq | $125 | $14,55213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Hamilton
- Peter ScheidlerHamilton$190K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.